National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme research funding and UK burden of disease

Abstract

BackgroundHTA Programme funding is governed by the need for evidence and scientific quality, reflecting funding of the National Institute for Health Research (NIHR) by the NHS. The need criterion incorporates covering the spectrum of diseases, but also taking account of research supported by other funders. This study compared the NIHR HTA Programme portfolio of research with the UK burden of disease as measured by Disability-adjusted Life Years (DALYs).MethodsA retrospective cross-sectional study using a cohort of all funded primary research and evidence syntheses projects received by the HTA Programme from April 2011 to March 2016 (n = 363); to determine the proportion of spend by disease compared with burden of disease in the UK calculated using 2015 UK DALY data.ResultsThe programme costing just under £44 million broadly reflected UK DALY burden by disease. Spend was lower than disease burden for cancer, cardiovascular and musculoskeletal diseases, which may reflect the importance of other funders, notably medical charities, which concentrate on these diseases.ConclusionThe HTA Programme spend, adjusted for other relevant funders, broadly matches disease burden in the UK; no diseases are being neglected.Electronic supplementary materialThe online version of this article (10.1186/s13063-018-2489-7) contains supplementary material, which is available to authorized users.

Changes in health in the countries of the UK and 150 English Local Authority areas 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

“…The National Institute for Health Research has used GBD data to assess the balance of their funded research portfolio. 14 GBD has also been used at a more granular level by bodies with an interest in addressing high burden conditions, such as mental health and musculoskeletal diseases, and by local Directors of Public Health. 15 Scotland has recently done its own independent analysis of its burden of disease.…”

A combination intervention addressing sexual risk-taking behaviors among vulnerable women in Uganda: study protocol for a cluster randomized clinical trial

“…Evidence-based microfinance for enhancing HIV prevention may better address structural factors that hinder traditional prevention efforts for WESW [33, 34]. Microfinance programs constitute one of the fastest growing anti-poverty strategies in developing countries [35].…”

Limited alignment of publicly competitive disease funding with disease burden in Japan

“…Given these potential contributors to decision-making about funding allocation, perfect alignment with DALYs or any other measure of disease burden would not be expected. However, faced with competing priorities for scarce resources on health research, DALYs, a comprehensive health measure that reflects the aging of the population and public health needs, should be considered as an important benchmark in assuming research priorities for funding decisions [2,3,5,[46][47][48][49][50]. For instance, after a long discussion on what indicators to consider in the US https://doi.org/10.1371/journal.pone.0228542.g002 [44,51,52], which is the largest investor in health R&D in the world [11]; the National Institutes of Health (NIH) noted in its recent strategic plan that DALYs would serve as a crucial consideration in aligning NIH's research priorities with public health needs [53].…”

“…The need to align investments in health research and development (R&D) with the public health needs is one of the most important public health challenges in Japan, as in other countries and the world [1][2][3][4][5][6][7][8][9][10]. According to the data from the Organisation for Economic Cooperation and Development (OECD), Japan's R&D expenditures (in all sectors, not just the health sector) are comparable to those of OECD countries.…”